Caixin Explains: What China’s First Securities Class-Action Lawsuit Means for the Stock Market
Long-suffering shareholders of indebted Kangmei Pharmaceutical Co. Ltd. (600518.SH), who lost money to 88.6 billion yuan ($ 13.9 billion) in fraud, got closer to compensation after two court rulings in the last three weeks.
On…